We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sengenics and Diploid Sign Exclusive Agreement
News

Sengenics and Diploid Sign Exclusive Agreement

Sengenics and Diploid Sign Exclusive Agreement
News

Sengenics and Diploid Sign Exclusive Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sengenics and Diploid Sign Exclusive Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sengenics has announced an exclusive partnership with Diploid, a Belgium-based Human Genome Interpretation service provider to enable more streamlined Clinical Exome and Genome sequencing in the Middle East and GCC countries. Key areas of collaboration include clinical exome and whole genome sequencing, cross-leveraging proprietary mutation databases and clinical interpretation by a panel of clinical geneticists.

Diploid’s CEO, Dr Peter Schols said “Sengenics has performed the highest number of genomics tests on children with developmental delay in Asia and the Middle-East to date, which has led to the development of their GalaxC™ database of Asian human disease mutations. We believe Sengenics experience coupled with Diploid’s advanced analysis and interpretation pipeline will benefit our current and future customers who mainly consist of clinicians who utilize exome sequencing for improving the accuracy of diagnosis. This integrated solution will be mutually advantageous in assisting both companies to work alongside doctors to enhance management of debilitating genetic disorders in the region.”

Sengenics and Diploid are also launching their new Exomax™ clinical exome sequencing services which offer enhanced coverage and fast turnaround options. Exomax™-Plus has a coverage that is nearly twice as high as standard exome capture methods. It includes additional exons, genes and UTRs. Whereas, Exomax-Rapid provides a shorter turnaround at just 20 working days.

Both Exomax options are offered at 30-40% lower in cost than the closest accredited competitor, which allows healthcare professionals to offer diagnoses and disease management in a timely fashion to more patients that really need it.

In addition, from January 2016, Sengenics Exomax™ service will come with a free user license to GalaxC™ for referring physicians. GalaxC™ is a proprietary Allele Frequency Database with more than 6.5 million unique Asian and Middle East pathogenic mutations and variants. It is designed to provide accurate clinical genomics information to physicians dealing with patients with inherited genetic diseases.

Exomax™ is the only clinical exome service that leverages the GalaxC™ allele frequency database to rule in pathogenic mutations and rule out population-based polymorphisms. This results in increased accuracy and diagnostic yield, and reduced false positives. Diploid and Sengenics will collaborate to widen the usage of the GalaxC™ database throughout the region.

Dr Stephen Moss, Head of Bioinformatics at Sengenics said “We are very much looking forward to merging our expertise, scalability and ideas with Diploid since their clinical genome interpretation service is among the best in the world. We have now worked together on over a thousand cases, of which the majority have been shown to be clinically valid. This is a powerful validation of Diploid’s informatics methodology and clinical expertise.”

Advertisement